Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michaela S. Donaldson"'
Publikováno v:
F1000Research, Vol 3 (2014)
Learning and memory as well as long-term potentiation (LTP) depend on Ca2+ influx through the NMDA-type glutamate receptor (NMDAR) and the resulting activation of the Ca2+ and calmodulin-dependent protein kinase (CaMKII). Ca2+ influx via the NMDAR tr
Externí odkaz:
https://doaj.org/article/d6a68303119e4eaabd6a19e90fd92336
Autor:
Aruni S. Arachchige-Don, Mary C. Horne, Tommaso Patriarchi, Michaela S. Donaldson, Maike Zimmermann
Publikováno v:
Cell cycle (Georgetown, Tex.), vol 15, iss 23
Definition of cell cycle control proteins that modify tumor cell resistance to estrogen (E2) signaling antagonists could inform clinical choice for estrogen receptor positive (ER+) breast cancer (BC) therapy. Cyclin G2 (CycG2) is upregulated during c
Publikováno v:
Journal of neurophysiology. 117(2)
The functional organization of the primary visual area (V1) and the importance of sensory experience in its normal development have been well documented in eutherian mammals. However, very few studies have investigated the response properties of V1 n
Autor:
Maike Zimmermann, Michaela S. Donaldson, Aruni S. Arachchige-Don, Robert F. Dallapiazza, Mary C. Horne, Colleen E. Cowan
Publikováno v:
Journal of Biological Chemistry. 287:22838-22853
To maintain genomic integrity DNA damage response (DDR), signaling pathways have evolved that restrict cellular replication and allow time for DNA repair. CCNG2 encodes an unconventional cyclin homolog, cyclin G2 (CycG2), linked to growth inhibition.
Autor:
Maike Zimmermann, Mary C. Horne, Michaela S. Donaldson, Tommaso Patriarchi, Aruni S. Arachchige Don
Publikováno v:
The FASEB Journal. 29
Resistance to estrogen (E2) receptor (ER) antagonists limits long-term abatement of ER+ breast cancer (BC). Defining cell cycle control proteins that modify tumor cell resistance to ER-antagonists ...
Autor:
Tommaso Patriarchi, Aruni S. Arachchige Don, Mary C. Horne, Maike Zimmerman, Michaela S. Donaldson
Publikováno v:
Cancer Research. 74:4559-4559
Ligand activated estrogen receptors (ER) drive growth of nearly two-thirds of breast cancers (BC). Acquired BC tumor resistance to endocrine-based therapeutics that inhibit ER signaling poses a significant challenge for long-term abatement of ER-posi